RxDoctor Payments DataLook up a doctor →

Mark Seredowych, MD

Internal Medicine · Santa Fe, NMNPI 1275545782

Payments from drug & device makers

$9,133in general payments, 2019–2025

Across 506 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$854
  • Lilly USA, LLC$702
  • Pfizer$536
  • Daiichi Sankyo Inc.$535
  • Johnson & Johnson$507
  • plus $5K from 44 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca52$1,005
Novo Nordisk43$854
Lilly USA, LLC29$702
Pfizer42$536
Daiichi Sankyo Inc.36$535
Johnson & Johnson31$507
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$416
Boehringer Ingelheim22$410
AbbVie(2 entities)19$355
Viatris Specialty LLC7$286
Aimmune Therapeutics, Inc.20$284
Amgen15$272
Nestle Healthcare Nutrition Inc.16$261
Astellas Pharma US Inc13$243
E.r. Squibb & Sons, L.L.C.12$191
Sanofi-aventis U.S. LLC10$180
Merck11$169
Mylan Specialty L.p.7$164
Novartis9$163
GSK10$159
Amarin Pharma, Inc.8$147
Eisai Inc.5$103
Bayer6$100
Otsuka America Pharmaceutical, Inc.4$99
Boston Scientific5$96
Grifols USA, LLC4$84
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$67
Exact Sciences4$66
Neurocrine Biosciences, Inc.4$62
Inspire Medical Systems, Inc.2$55
Abbott3$47
Philips North America LLC2$47
Idorsia Pharmaceuticals US Inc3$46
Biodelivery Sciences International, Inc.3$43
Actelion Pharmaceuticals US, Inc.2$42
Radius Health, Inc.2$39
Baxter Healthcare2$30
Irhythm Technologies, Inc.1$29
Smith+Nephew2$29
Phathom Pharmaceuticals, Inc.1$26
Abiomed1$24
IBSA Pharma Inc.1$23
Itamar Medical Inc1$22
Bioventus LLC1$20
Lundbeck LLC1$18
Vertex1$17
Teva Pharmaceuticals USA, Inc.1$17
Kerecis Limited1$15
Dexcom, Inc.1$14
Biohaven Pharmaceuticals, Inc.1$13

How this compares

$9,133 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico →

Medicare billing

Part B allowed, 2024
$173,960
Medicare patients
391
Services billed
2,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Santa Fe

See the full list for New Mexico →

Where these figures come from

Is this you, or does something look wrong? →